Obermatt
See Similar Stocks →

Flags

Financial distress

Heron Therapeutics

NAQ:HRTX · US4277461020
BiotechnologySmall

360

42
Profit price55
Owner Earnings Yield1
Dividend Yield1
Price/Sales100
EV / Gross Profit83
Price/Book100
Return on Capital82
Cash Return on Capital93
Return on Equity98
Profit margins80
Accruals42
Owner Earnings Margin85
Sales growth49
Profit growth79
Reinvestment34
Price momentum4
Debt load19
Refinancing100
Debt Payback1
Liquidity77
Analyst ratings13
Expectations trend50
Market mood44
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Heron Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded1987
Employees164
Websiteherontx.com
ISINUS4277461020
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Pain ManagementInflammationCentral Nervous SystemNeurologyOncologySurgeryBiotechnologyHealth CareTherapeutics

Description

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. The company’s advanced science, patented technologies…

Analysis

Quality compounder

Heron Therapeutics, Inc. is a quality compounder: a well-run business trading at a price that reflects what it is worth.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is stretched. The company scores 2/20 on our value-creation score: not creating value.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
72
2026

All-time high

72

Jun 2026

All-time low

51

Mar 2026

Average rank

62

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
100
—
—
—
Price/Earnings
69
—
—
—
Price/Book
100
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
97
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Heron Therapeutics with its peers
MediciNova
NMQ:MNOV
21
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Protara Therapeutics
NMQ:TARA
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Aura Biosciences
NMQ:AURA
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tenaya Therapeutics
NSQ:TNYA
29
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Seres Therapeutics
NSQ:MCRB
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
BioCryst Pharmaceuticals
NSQ:BCRX
52
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →